Document is current
Any future updates will be listed below
-
Authors
Gottimukkala, Karthikeya S. V.
Lane, Daniel D.
Cunningham, Rachel
Malik, Haleema S.
Jwa, Youngseo
Cassidy, Molly E.
Castelli, Jack M. P. https://orcid.org/0000-0001-5834-0620
Enstrom, Mark R.
Poljakov, Katrina
Gastelum, Grady
Ho, Samuel H. https://orcid.org/0000-0001-7647-0752
Tassa, Carlos
Adair, Jennifer E. https://orcid.org/0000-0003-4599-016X
- License Information
-
More Information
Article History
Received: 16 July 2025
Revised: 5 November 2025
Accepted: 18 December 2025
First Online: 14 January 2026
Competing interests
: JEA is a co-inventor on U.S. Patent WO2018226762A1 entitled “Genomic Safe Harbors for Genetic Therapies in Human Stem Cells and Engineered Nanoparticles to Provide Targeted Genetic Therapies”. All other authors declare no competing interests.
: Healthy adults donated cells for this study through the Core Center of Excellence in Hematology at Fred Hutchinson Cancer Center under an approved protocol (no. 985.03), which was compliant with the Declaration of Helsinki and Belmont Report.
